Novartis announced FDA approval for Fabhalta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
December 6, 2023 12:19 AM ESTApproval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels 2 g/dL (82.3% vs. 0%) and hemoglobin level 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment1,2 Fabhalta, now available for both previously treated and treatment-naïve patients, is the only FDA-approved Factor B inhibitor of the... More
